Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody

IMAB362/Zolbetuximab, a first-in-class IgG1 antibody directed against the cancer-associated gastric-lineage marker CLDN18.2, has recently been reported to have met its primary endpoint in two phase 3 trials as a first-line treatment in combination with standard of care chemotherapy in CLDN18.2-posit...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Hayat Bähr-Mahmud, Ursula Ellinghaus, Christiane R. Stadler, Leyla Fischer, Claudia Lindemann, Anuhar Chaturvedi, Jan Diekmann, Stefan Wöll, Imke Biermann, Bernhard Hebich, Caroline Scharf, Manuela Siefke, Alexandra S. Roth, Martin Rao, Kerstin Brettschneider, Eva-Maria Ewen, Uğur Şahin, Özlem Türeci
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Taylor & Francis Group 2023-12-01
Saila:OncoImmunology
Gaiak:
ADCC
BNT141
human CLDN18.2
IMAB362
immunotherapy
RiboMab
Sarrera elektronikoa:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2255041

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2255041

Antzeko izenburuak